2018 Press Releases

Keyword Search
 
DateTitle 
01/07/18Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer
SAN DIEGO, Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Christopher O'Brien, M.D., Chief Medical Officer, has notified the Company he plans to retire in February 2018, after a transition period with his successor. Dr. O'Brien joined Neurocrine in 2005, and has led the clinical development and medical affairs activities for more than 12 years. Dr. O'Brien will remain ... 
Printer Friendly Version
01/07/18Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017 - INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $64 Million with Approximately 9,100 TRx - Received $30 Million Milestone from AbbVie for the Elagolix Endometriosis NDA Acceptance During the Fourth Quarter of 2017 - INGREZZA® (valbenazine) Preliminary Net Product Sales of Approximately $116 Million with Approximately 14,... 
Printer Friendly Version
01/02/18Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast Will be on January 8, 2018 SAN DIEGO, Jan. 2, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, Jan. 8, 2018, in San Francisco. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A replay of the presentation will ... 
Printer Friendly Version